Navigation Links
PROMUS Element™ Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study
Date:5/20/2011

er protocol population included cardiac death related to the target vessel (2.4 percent), myocardial infarction related to the target vessel (MI, 0.0 percent) and ischemia-driven target lesion revascularization (TLR, 0.0 percent).  Clinical outcome rates at 12 months in the intent-to-treat population were also low for cardiac death (3.3 percent), MI (0.0 percent), TLR (2.2 percent) and ARC definite/probable stent thrombosis (0.0 percent).

"The PLATINUM Small Vessel data build on the positive outcomes from the PLATINUM Workhorse and QCA studies, confirming the successful transfer of favorable outcomes associated with everolimus to the novel platinum chromium (PtCr) stent design," said Keith D. Dawkins, M.D., Senior Vice President and Chief Medical Officer for Boston Scientific's Cardiology, Rhythm and Vascular Group.  "The results demonstrate a highly effective PtCr small vessel stent platform with an excellent safety profile."

"Boston Scientific has led development of drug-eluting stents for small vessels, which now represent approximately 10 percent of coronary stenting procedures," said Hank Kucheman, Executive Vice President and Group President, Cardiology, Rhythm and Vascular for Boston Scientific.  "This evaluation of the 2.25 mm PROMUS Element Stent reconfirms our commitment to providing a complete range of solutions and sizes for physicians and their patients."

The PLATINUM clinical program is evaluating the safety and effectiveness of the PROMUS Element Stent in five multi-center studies totaling more than 1,800 patients, including a global, randomized, pivotal controlled trial in workhorse lesions, and single-arm studies evaluating small vessels, long lesions, pharmacokinetics, and quantitative coronary angiography and intravascular ultrasound data.  

The PROMUS Element Stent System received CE Mark approval and was launched in Europe and other international markets in 2009.  It features an innovative PtC
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Launches PROMUS® Element™ and TAXUS® Element™ Stent Systems in India
2. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
3. Boston Scientific Announces Clinical Data Supporting Safety and Efficacy of Platinum Chromium PROMUS Element™ Stent
4. Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System
5. SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS(R) and TAXUS(R) Express(R) Stents
6. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
7. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
8. Boston Scientifics TAXUS® Element™ Stent Demonstrates Strong Outcomes in Diabetic Patients
9. OrbusNeichs Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011
10. InspireMD Increases Geographic Penetration; MGuard Stent is Now Available in India
11. Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
(Date:9/1/2015)... ... September 01, 2015 , ... The Capillus82™ ... treatment of androgenic alopecia in adults, announces Miami-based medical device manufacturer, Capillus, LLC. ... also demonstrating its safety when used at home to combat hair loss. ...
(Date:9/1/2015)... Louisville, KY (PRWEB) , ... September 01, 2015 ... ... private practice physical therapy company, is pleased to announce their partnership with ... The merger allows both groups to continue to provide kind, compassionate, and empathetic ...
(Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary Hospital ... from ages 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community College in ... counselors, some of whom work for Calvary, and two junior counselors who were campers ...
(Date:9/1/2015)... London, UK (PRWEB) , ... ... ... are constantly seeking better therapeutic options to efficiently cure and prevent different ... classes. Different cancers have different pathophysiological properties due to which distinctive approach ...
(Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure wound ... a wound to remove exudates, fluid, and infectious materials to prepare the wound ... devices, disposable devices, and canisters, etc.) is projected to expand continuously through 2021. ...
Breaking Medicine News(10 mins):Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3
... new information at 6- and 12-months-old, typically excel ... in their 20,s, according to a study directed ... Fagan,s "The prediction, from infancy, of adult IQ and ... receiving accolades. Mensa International, Limited,- the international organization of ...
... of the outcomes of medical tests whose results are ... is common and can lead to serious medical errors ... by researchers from the Regenstrief Institute and the Indiana ... summaries are grossly inadequate at documenting both tests with ...
... , ... LearnSomething Team-Up to and Unveil the Health Communicator , ... Burtonsville, MD (PRWEB) August 7, 2009 -- ... monitors and health testing stations, will be exhibiting its current products and technologies at ...
... 7 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), ... Co., Ltd. (Mellow Hope) announced today that the general ... in regards to a significant new business development opportunity ... company intends to participate in a formal tender process ...
... , , , MINNEAPOLIS, Aug. ... National Courage Award on Aug. 15. The annual award recognizes ... with disabilities. The award is being presented during the Medtronic ... Depot in Minneapolis. , , "To be included ...
... , , , JEDDAH, ... to feel beautiful and good about themselves, and Saudi women ... Islam, which is such a strong guiding force in the ... this strict Muslim country. , http://susiesbigadventure.blogspot.com/2009/08/plastic-surgery-in-saudi-arabia.html ...
Cached Medicine News:Health News:Ability to process information as a baby continues into adulthood 2Health News:Fumbled handoffs can lead to medical errors 2Health News:Lifeclinic to Showcase Health Stations and Health Communicator at the National Association of Chain Drug Stores 2009 Pharmacy and Technology Conference 2Health News:Lifeclinic to Showcase Health Stations and Health Communicator at the National Association of Chain Drug Stores 2009 Pharmacy and Technology Conference 3Health News:Lifeclinic to Showcase Health Stations and Health Communicator at the National Association of Chain Drug Stores 2009 Pharmacy and Technology Conference 4Health News:Hard To Treat Diseases (HTDS) Chile Flu Vaccine Tender 2Health News:Hard To Treat Diseases (HTDS) Chile Flu Vaccine Tender 3Health News:Hard To Treat Diseases (HTDS) Chile Flu Vaccine Tender 4Health News:Courage Center Presents 2009 National Courage Award to Jordan Thomas 2Health News:Courage Center Presents 2009 National Courage Award to Jordan Thomas 3
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: